Lange, Elizabeth Cunera Maria de 1962-
![Sudoc [ABES], France](/viaf/images/flags/SUDOC.png "Sudoc [ABES], France")
Elizabeth C de Lange
Lange, Elizabeth C. M. de
Lange, Esther
VIAF ID: 288847735 (Personal)
Permalink: http://viaf.org/viaf/288847735
Preferred Forms
-
100 0 _
‡a
Elizabeth C de Lange
-
100 1 _ ‡a Lange, Elizabeth C. M. de
-
100 1 _
‡a
Lange, Elizabeth C. M. de
-
100 1 _ ‡a Lange, Elizabeth Cunera Maria de ‡d (1962- ).
-
100 1 _
‡a
Lange, Elizabeth Cunera Maria de
‡d
1962-
-
100 1 _ ‡a Lange, Elizabeth Cunera Maria de, ‡d 1962-
-
100 1 _
‡a
Lange, Elizabeth Cunera Maria de,
‡d
1962-....
-
100 1 _
‡a
Lange, Elizabeth Cunera Maria de
‡d
1962-
-
100 1 _ ‡a Lange, Esther
4xx's: Alternate Name Forms (19)
5xx's: Related Names (4)
- 510 2 _
‡a
American Association of Pharmaceutical Scientists
- 510 2 _
‡a
Rijksuniversiteit Leiden
- 510 2 _
‡a
Rijksuniversiteit Leiden
‡e
Affiliation
- 510 2 _
‡a
Springer Science+Business Media
Works
| Title | Sources |
|---|---|
| [11C]phenytoin revisited: synthesis by [11C]CO carbonylation and first evaluation as a P-gp tracer in rats |
|
| [11C]quinidine and [11C]laniquidar PET imaging in a chronic rodent epilepsy model: impact of epilepsy and drug-responsiveness |
|
| The 3D Brain Unit Network Model to Study Spatial Brain Drug Exposure under Healthy and Pathological Conditions |
|
| Age-associated physiological and pathological changes at the blood-brain barrier: A review. |
|
| Åh disko drenge og piger |
|
| Altered GABAA receptor density and unaltered blood-brain barrier transport in a kainate model of epilepsy: an in vivo study using 11C-flumazenil and PET. |
|
| Analgosedation in paediatric severe traumatic brain injury (TBI): practice, pitfalls and possibilities. |
|
| Application of ED-optimality to screening experiments for analgesic compounds in an experimental model of neuropathic pain |
|
| Biomarkers in epilepsy-A modelling perspective |
|
| Blood-Based Biomarkers of Quinpirole Pharmacology: Cluster-Based PK/PD and Metabolomics to Unravel the Underlying Dynamics in Rat Plasma and Brain |
|
| Bundling arrows: improving translational CNS drug development by integrated PK/PD-metabolomics. |
|
| Correction to: Access to the CNS: Biomarker Strategies for DopaminergicTreatments |
|
| Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat. |
|
| Diurnal variation in P-glycoprotein-mediated transport and cerebrospinal fluid turnover in the brain |
|
| Drug deliveryto the brain : physiological concepts, methodologies and approaches |
|
| Drug equilibration across the blood-brain barrier--pharmacokinetic considerations based on the microdialysis method |
|
| Emerging Insights for Translational Pharmacokinetic and Pharmacokinetic-Pharmacodynamic Studies: Towards Prediction of Nose-to-Brain Transport in Humans |
|
| Evaluation of blood-brain barrier transport and CNS drug metabolism in diseased and control brain after intravenous L-DOPA in a unilateral rat model of Parkinson's disease |
|
| The exploration of rotenone as a toxin for inducing Parkinson's disease in rats, for application in BBB transport and PK-PD experiments. |
|
| Fingerprints of CNS drug effects: a plasma neuroendocrine reflection of D receptor activation using multi-biomarker pharmacokinetic/pharmacodynamic modelling |
|
| From receptor binding kinetics to signal transduction; a missing link in predicting in vivo drug-action |
|
| Functions of the CB1 and CB 2 receptors in neuroprotection at the level of the blood-brain barrier |
|
| Glutathione PEGylated liposomes: pharmacokinetics and delivery of cargo across the blood-brain barrier in rats. |
|
| The Impact of Liposomal Formulations on the Release and Brain Delivery of Methotrexate: An In Vivo Microdialysis Study |
|
| The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid. |
|
| The implications of target saturation for the use of drug-target residence time |
|
| In vitro and in silico analysis of the effects of D receptor antagonist target binding kinetics on the cellular response to fluctuating dopamine concentrations |
|
| In vitro and in vivo investigations on fluoroquinolones; effects of the P-glycoprotein efflux transporter on brain distribution of sparfloxacin. |
|
| In Vivo Quantitative Understanding of PEGylated Liposome's Influence on Brain Delivery of Diphenhydramine |
|
| In vivo Target Residence Time and Kinetic Selectivity: The Association Rate Constant as Determinant |
|
| The influence of drug distribution and drug-target binding on target occupancy: The rate-limiting step approximation |
|
| Influence of plasma protein binding on pharmacodynamics: Estimation of in vivo receptor affinities of beta blockers using a new mechanism-based PK-PD modelling approach. |
|
| LUF7244, an allosteric modulator/activator of Kv 11.1 channels, counteracts dofetilide-induced torsades de pointes arrhythmia in the chronic atrioventricular block dog model |
|
| Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans. |
|
| Mechanistic models enable the rational use of in vitro drug-target binding kinetics for better drug effects in patients |
|
| Mechanistic Study on the Use of the l-Type Amino Acid Transporter 1 for Brain Intracellular Delivery of Ketoprofen via Prodrug: A Novel Approach Supporting the Development of Prodrugs for Intracellular Targets |
|
| Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity |
|
| Modelling the delay between pharmacokinetics and EEG effects of morphine in rats: binding kinetic versus effect compartment models |
|
| Multivariate pharmacokinetic/pharmacodynamic (PKPD) analysis with metabolomics shows multiple effects of remoxipride in rats |
|
| The need for mathematical modelling of spatial drug distribution within the brain |
|
| A new minimal-stress freely-moving rat model for preclinical studies on intranasal administration of CNS drugs. |
|
| Next-generation biomarker discovery in Alzheimer's disease using metabolomics - from animal to human studies |
|
| A novel CCR2 antagonist inhibits atherogenesis in apoE deficient mice by achieving high receptor occupancy |
|
| Online solid phase extraction with liquid chromatography-tandem mass spectrometry to analyze remoxipride in small plasma-, brain homogenate-, and brain microdialysate samples. |
|
| P-glycoprotein-mediated efflux of antiepileptic drugs: preliminary studies in mdr1a knockout mice. |
|
| P-glycoprotein protein expression versus functionality at the blood-brain barrier using immunohistochemistry, microdialysis and mathematical modeling |
|
| Penetration of dexamethasone into brain glucocorticoid targets is enhanced in mdr1A P-glycoprotein knockout mice. |
|
| Pharmacokinetic/pharmacodynamic modelling of the EEG effects of opioids: the role of complex biophase distribution kinetics. |
|
| Population pharmacokinetic modelling of non-linear brain distribution of morphine: influence of active saturable influx and P-glycoprotein mediated efflux. |
|
| Potential role of ABC transporters as a detoxification system at the blood-CSF barrier. |
|
| Preclinical prediction of human brain target site concentrations: considerations in extrapolating to the clinical setting. |
|
| Prediction of human CNS pharmacokinetics using a physiologically-based pharmacokinetic modeling approach. |
|
| Prediction of methotrexate CNS distribution in different species - influence of disease conditions. |
|
| Quantitative microdialysis using modified ultraslow microdialysis: direct rapid and reliable determination of free brain concentrations with the MetaQuant technique. |
|
| (R)-[11C]PK11195 brain uptake as a biomarker of inflammation and antiepileptic drug resistance: evaluation in a rat epilepsy model. |
|
| (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus |
|
| Repeated microdialysis perfusions: periprobe tissue reactions and BBB permeability |
|
| Reproducible and time-dependent modification of serum protein binding in Wistar Kyoto rats |
|
| Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling |
|
| Simultaneous in vivo measurements of receptor density and affinity using [11C]flumazenil and positron emission tomography: comparison of full saturation and steady state methods. |
|
| Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats |
|
| Synthesis and preclinical evaluation of [11C]D617, a metabolite of (R)-[11C]verapamil |
|
| Systemic and direct nose-to-brain transport pharmacokinetic model for remoxipride after intravenous and intranasal administration. |
|
| T lymphocytes impair P-glycoprotein function during neuroinflammation. |
|
| Target and Tissue Selectivity Prediction by Integrated Mechanistic Pharmacokinetic-Target Binding and Quantitative Structure Activity Modeling. |
|
| Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat. |
|
| Targeted brain delivery of methotrexate by glutathione PEGylated liposomes: How can the formulation make a difference? |
|
| Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients. |
|
| Transport across the blood-brain barrier: stereoselectivity and PET-tracers. |
|
| Understanding the Behavior of Systems Pharmacology Models Using Mathematical Analysis of Differential Equations: Prolactin Modeling as a Case Study |
|
| The use of intracerebral microdialysis for the determination of pharmacokinetic profiles of anticancer drugs in tumor-bearing rat brain |
|
| The use of intracerebral microdialysis to study blood-brain barrier transport characteristics of drugs |
|
| Utility of Animal Models to Understand Human Alzheimer's Disease, Using the Mastermind Research Approach to Avoid Unnecessary Further Sacrifices of Animals |
|
| Utility of CSF in translational neuroscience. |
|
| White paper: landscape on technical and conceptual requirements and competence framework in drug/disease modeling and simulation. |
|
